Polpharma Biologics and Tuteur Sign LATAM Autoimmune Biosimilar Deal
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
MONTREAL, Dec. 17, 2025 — Bristol Myers Squibb Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive...
